Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Petros Pharmaceuticals, Inc. (PTPI)

0.4327   -0.005 (-1.14%) 11-28 10:47
Open: 0.45 Pre. Close: 0.4377
High: 0.45 Low: 0.42
Volume: 5,954 Market Cap: 9(M)

Technical analysis

as of: 2022-11-28 10:21:21 AM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0.6     One year: 0.71
Support: Support1: 0.37    Support2: 0.31
Resistance: Resistance1: 0.52    Resistance2: 0.6
Pivot: 0.45
Moving Average: MA(5): 0.43     MA(20): 0.46
MA(100): 0.61     MA(250): 1.17
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 30     %D(3): 23.6
RSI: RSI(14): 46.9
52-week: High: 5.19  Low: 0.37
Average Vol(K): 3-Month: 129 (K)  10-Days: 61 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PTPI ] has closed above bottom band by 43.0%. Bollinger Bands are 35.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.46 - 0.46 0.46 - 0.47
Low: 0.43 - 0.43 0.43 - 0.43
Close: 0.43 - 0.43 0.43 - 0.44

Company Description

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Headline News

Thu, 17 Nov 2022
Petros Pharmaceuticals Third Quarter 2022 Earnings: US$0.67 loss per share (vs US$0.17 loss in 3Q 2021) - Simply Wall St

Tue, 15 Nov 2022
Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update - Yahoo Finance

Tue, 25 Oct 2022
Petros Pharma stock jumps ~22% after erectile dysfunction drug gets label expansion - Seeking Alpha

Thu, 28 Jul 2022
Petros Pharmaceuticals says purported acquisition of company is fraudulent - Seeking Alpha

Wed, 06 Apr 2022
Mary Jean Eisenhower and parents react to People to People International filing bankruptcy - Abilene Recorder Chronicle

Tue, 18 Jan 2022
Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug STENDRA® (avanafil) - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 21 (M)
Shares Float 15 (M)
% Held by Insiders 29.9 (%)
% Held by Institutions 3.8 (%)
Shares Short 149 (K)
Shares Short P.Month 77 (K)

Stock Financials

EPS -0.9
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1
Profit Margin (%) 0
Operating Margin (%) -455.8
Return on Assets (ttm) -27.5
Return on Equity (ttm) -124.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.29
Sales Per Share 0.2
EBITDA (p.s.) -0.65
Qtrly Earnings Growth 0
Operating Cash Flow -20 (M)
Levered Free Cash Flow -32 (M)

Stock Valuations

PE Ratio -0.51
PEG Ratio 0
Price to Book value 0.44
Price to Sales 2.15
Price to Cash Flow -0.48

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.